consensu
statement
american
colleg
veterinari
intern
medicin
acvim
provid
veterinari
commun
uptod
inform
pathophysiolog
diagnosi
treatment
clinic
import
anim
diseas
acvim
board
regent
overse
select
relev
topic
identif
panel
member
expertis
draft
statement
aspect
assur
integr
process
statement
deriv
evidencebas
medicin
whenev
possibl
panel
offer
interpret
comment
evid
inadequ
contradictori
draft
prepar
panel
follow
solicit
input
acvim
membership
may
incorpor
statement
submit
journal
veterinari
intern
medicin
edit
prior
public
author
sole
respons
content
statement
immunemedi
hemolyt
anemia
imha
import
caus
morbid
mortal
dog
imha
also
occur
cat
although
less
commonli
imha
consid
secondari
attribut
underli
diseas
primari
idiopath
caus
found
elimin
diseas
caus
imha
may
attenu
stop
immunemedi
erythrocyt
destruct
advers
consequ
longterm
immunosuppress
treatment
avoid
infect
cancer
drug
vaccin
inflammatori
process
may
underli
caus
imha
evid
comorbid
systemat
evalu
render
evidencebas
decis
difficult
identifi
extract
data
studi
publish
veterinari
literatur
develop
novel
tool
evalu
evid
qualiti
use
assess
studi
design
diagnost
criteria
immunemedi
hemolyt
anemia
imha
dog
cat
associ
high
morbid
mortal
pathogen
autoantibodi
target
erythrocyt
membran
epitop
provid
mechan
fraction
crystalliz
receptormedi
extravascular
hemolysi
mediat
macrophag
complement
interact
antibodi
bound
erythrocyt
facilit
extravascular
hemolysi
caus
intravascular
hemolysi
format
membran
attack
complex
expediti
diagnosi
distinguish
imha
caus
anemia
critic
rapid
institut
appropri
treatment
variou
criteria
diagnosi
imha
describ
literatur
base
document
immunemedi
erythrolysi
proxi
marker
phenomenon
hereaft
denot
import
refer
manag
softwar
mendeley
elsevi
new
york
endnot
clariv
analyt
philadelphia
manual
screen
basi
inclus
criteria
outlin
support
inform
refer
list
paper
also
examin
captur
refer
cite
medlin
web
scienc
pathogenspecif
search
conduct
captur
addit
refer
support
inform
design
novel
qualiti
assess
data
extract
tool
includ
domain
captur
inform
studi
design
qualiti
q
confid
comorbid
diagnosi
c
likelihood
causal
link
comorbid
imha
l
confid
imha
diagnosi
number
patient
given
comorbid
n
purpos
studi
term
comorbid
includ
exposur
drug
toxin
vaccin
addit
domain
captur
detail
inform
comorbid
includ
statist
infer
avail
comorbid
summar
broad
categori
infecti
diseas
cancer
inflammatori
diseas
drug
toxin
vaccin
panel
member
nonpanel
vcci
task
forc
member
assign
random
pair
purpos
data
extract
qualiti
assess
divid
total
number
paper
equal
among
pair
concord
among
pair
sought
individu
member
disagre
specif
observ
observ
relat
qualiti
assess
confirm
lk
oag
comorbid
identifi
paper
integr
metric
evid
ime
comput
sum
normal
score
weight
accord
assess
rel
import
evid
rate
long
comorbid
present
individu
patient
henc
ime
q
c
n
comorbid
present
individu
patient
includ
infect
agent
ime
valu
calcul
refer
patient
nevertheless
made
narr
yield
insight
score
assess
posit
question
studi
ask
whether
comorbid
induc
associ
imha
part
anemiaanaemia
anemiaanaemiaimmun
anemiaanaemiaimmun
inclus
anemiaanaemiaimmun
inclus
anemiaanaemiaimmun
inclusioncomorbid
anemiaanaemiaimmun
reject
manual
curat
duplic
anemiaanaemiaimmun
inclusionreject
curat
record
paper
captur
search
algorithm
anemia
met
inclus
criteria
n
manual
curat
remov
duplic
n
remain
paper
screen
assess
whether
mention
comorbid
yield
paper
addit
ad
march
independ
search
infecti
agent
yield
addit
paper
relev
one
addit
paper
identifi
examin
refer
list
captur
paper
imha
immunemedi
hemolyt
anemia
hypothesi
specif
aim
question
comorbid
induc
associ
imha
answer
studi
design
answer
ye
score
assign
answer
studi
design
descript
associ
comorbid
assign
arbitrari
score
lowest
possibl
maximum
q
score
comput
comorbid
assign
descript
associ
gener
studi
qualiti
case
irrelev
question
causal
relationship
comorbid
imha
q
score
case
therefor
maximum
normal
score
criterion
yield
maximum
ime
valu
minimum
ime
valu
appli
studi
present
evid
comorbid
associ
imha
comorbid
within
paper
conserv
score
ime
criteria
appli
relev
cohort
patient
avoid
exagger
evid
threshold
ime
valu
comput
allow
comorbid
design
neglig
low
intermedi
high
evid
causal
relationship
imha
threshold
neglig
low
evid
taken
hypothet
descript
associ
studi
intermedi
c
l
score
posit
case
ime
threshold
low
intermedi
evid
taken
hypothet
crosssect
studi
q
score
intermedi
c
l
score
posit
case
ime
final
threshold
intermedi
high
evid
taken
hypothet
prospect
cohortcasecontrol
studi
q
score
high
c
score
intermedi
l
score
high
score
mechanist
base
posit
case
ime
qualiti
assess
data
extract
tool
shown
support
inform
support
inform
show
deriv
score
q
c
l
n
hemolysi
also
emphas
test
neither
specif
sensit
aiha
diagnost
test
describ
therefor
interpret
combin
result
diagnost
test
respons
immunosuppress
lack
gold
criterion
standard
also
present
challeng
interpret
literatur
exampl
although
sensit
specif
discuss
either
report
directli
referenc
studi
calcul
panel
use
data
within
refer
criteria
use
defin
case
posit
neg
imha
vari
variabl
also
exist
test
perform
valid
therefor
perform
studi
may
gener
other
cogniz
caveat
panel
member
consid
algorithm
figur
appropri
diagnosi
primari
secondari
imha
complement
follow
explanatori
note
one
panel
member
consid
marker
immunemedi
diseas
assess
caution
absenc
hemolysi
discuss
restrict
immunemedi
destruct
circul
erythrocyt
ie
precursortarget
immunemedi
anemia
pure
red
cell
aplasia
discuss
reader
requir
addit
inform
immunemedi
differenti
failur
destruct
level
bone
marrow
refer
elsewher
spun
pcv
suggest
calcul
hematocrit
may
unreli
agglutin
present
howev
studi
human
report
increas
plasma
trap
abnorm
erythrocyt
eg
spherocyt
could
introduc
inaccuraci
spun
pcv
best
knowledg
effect
agglutin
spherocytosi
spun
pcv
investig
veterinari
speci
lack
regener
assess
reticulocyt
count
elimin
imha
approxim
dog
nonregen
anemia
present
sign
immunemedi
destruct
spherocyt
use
diagnost
criterion
dog
felin
erythrocyt
consist
display
central
pallor
interpret
spherocyt
blood
transfus
done
cautious
store
blood
product
may
contain
high
proport
spherocyt
spherocyt
document
human
patient
hemolyt
transfus
reaction
spherocytosi
assess
monolay
wellmad
blood
smear
spherocytelik
artifact
aris
toward
feather
edg
thick
area
anem
anim
spherocyt
confirm
deeper
monolay
avoid
artifact
thin
area
spherocytosi
also
induc
increas
osmot
fragil
dyserythropoiesi
hereditari
spectrin
defici
also
potenti
may
give
rise
spherocyt
smear
made
blood
store
hour
percentag
spherocyt
blood
smear
human
patient
mutat
caus
hereditari
spherocytosi
variabl
high
literatur
search
canin
hereditari
spherocytosi
identifi
case
mark
spherocytosi
singl
studi
oil
immers
field
yield
sensit
confid
interv
ci
ci
provid
author
onlin
medcalc
diagnost
f
g
u
r
e
diagnost
algorithm
immunemedi
hemolyt
anemia
imha
identifi
anemia
patient
biomark
immunemedi
destruct
next
assess
includ
salin
agglutin
test
sat
direct
antiglobulin
test
dat
andor
flow
cytometri
fc
least
present
posit
sat
persist
wash
make
firm
diagnosi
imha
sign
hemolysi
assess
least
present
firm
diagnosi
variat
theme
would
yield
support
suspici
diagnosi
provid
anoth
caus
anemia
identifi
addit
abbrevi
least
dz
diseas
test
evalu
calcul
http
wwwmedcalcorgcalcdiagnost
testphp
use
calcul
specif
ci
imha
dog
compar
sensit
ci
specif
ci
c
oil
immers
field
threshold
oil
immers
field
therefor
could
consid
support
diagnosi
imha
oil
immers
field
also
may
consist
imha
provid
caus
spherocytosi
identifi
threshold
similar
criteria
spherocytosi
propos
semiquantit
grade
system
spherocyt
number
low
versu
typic
abund
extravascular
imha
variabl
among
field
could
issu
calcul
mean
count
sever
field
eg
could
help
establish
true
extent
spherocytosi
enrol
case
imha
research
highqual
blood
smear
use
given
pitfal
spherocyt
recognit
examin
smear
boardcertifi
clinic
pathologist
advantag
although
evalu
dri
blood
smear
hematolog
instrument
scatter
plot
suggest
agglutin
panel
consid
techniqu
adequ
confirm
agglutin
base
possibl
overlap
rouleaux
blood
smear
potenti
caus
macrocyt
scattergram
evalu
salin
agglutin
test
perform
mix
drop
salin
drop
blood
report
specif
ci
c
imha
dog
mix
blood
salin
yield
specif
ci
c
base
dog
without
imha
ci
c
anem
dog
consid
agglutin
persist
mix
drop
blood
drop
salin
therefor
consid
adequ
evid
agglutin
case
consider
higher
dilut
ratio
aid
microscop
identif
agglutin
decreas
fals
posit
confirm
agglutin
persist
wash
erythrocyt
time
ratio
salin
recommend
anim
equivoc
result
eg
rare
small
erythrocyt
clump
otherwis
neg
test
markedli
increas
total
protein
eg
leishmaniasi
multipl
myeloma
felin
infecti
periton
fip
fibrinogen
concentr
strong
rouleaux
format
blood
smear
examin
base
report
agglutin
wash
erythrocyt
normal
dog
c
suggest
salin
solut
room
temperatur
c
five
panel
member
prefer
direct
coomb
test
dat
consid
flow
cytometri
dat
equal
use
support
inform
provid
recommend
perform
test
dat
perform
agglutin
persist
wash
combin
anemia
hemolysi
persist
agglutin
suffici
diagnosi
imha
immunochromatographi
offer
altern
convent
dat
flow
cytometri
confirm
neg
result
convent
dat
may
advis
frequent
weak
posit
test
strip
datposit
dog
dat
sensit
rang
dog
cat
studi
report
reli
dat
alon
diagnosi
imha
report
sensit
suffici
inform
calcul
specif
dat
dog
cat
studi
publish
report
specif
suffici
inform
calcul
although
small
experiment
studi
report
sensit
flow
cytometri
sensit
ci
c
larger
studi
report
result
routin
clinic
test
studi
includ
clinic
ill
neg
control
specif
flow
cytometri
ci
ci
c
report
sampl
handl
effect
flow
cytometri
lack
storag
sampl
c
day
dat
test
accept
unless
laboratori
advis
otherwis
howev
clinic
valu
percentag
posit
erythrocyt
evalu
rigor
dog
spherocyt
assess
describ
provid
evid
hemolysi
consist
evid
phenomenon
human
erythrocyt
increas
rigid
spherocyt
result
entrap
within
spleen
subsequ
extravascular
hemolysi
absenc
decreas
function
hepat
mass
obstruct
cholestasi
sepsi
hyperbilirubinemia
may
repres
evid
hemolysi
least
follow
consid
suffici
evid
hyperbilirubinemia
icteru
total
serum
plasma
bilirubin
concentr
refer
interv
bilirubinuria
cat
bilirubin
urin
reagent
strip
dog
bilirubin
report
hemolyz
sampl
interpret
combin
inform
regard
like
impact
hemolysi
assay
hemoglobinemia
detect
visual
examin
plasma
measur
cellfre
hemoglobin
use
instrumentbas
indic
hemolysi
limit
individu
method
consid
exampl
spectrophotometr
hemolyt
indic
reli
manufacturerspecif
method
algorithm
directli
compar
among
differ
instrument
similarli
discrep
mean
cell
hemoglobin
concentr
cellular
hemoglobin
concentr
provid
advia
hematolog
instrument
may
reflect
hemolysi
sampl
characterist
lipemia
hemoglobinemia
interpret
evid
hemolysi
elimin
artifactu
hemolysi
common
caus
vitro
hemolysi
includ
limit
traumat
venipunctur
freez
storag
base
studi
human
sampl
via
iv
cathet
postcollect
inject
sampl
vacutain
likelihood
vitro
hemolysi
increas
factor
increas
erythrocyt
fragil
present
eg
lipemia
provid
caus
myoglobinuria
absent
hemoglobinuria
consid
present
urin
red
discolor
clear
centrifug
posit
heme
reaction
urin
dipstick
present
absenc
intact
erythrocyt
microscop
sediment
examin
assess
hemoglobinuria
perform
use
fresh
urin
sampl
anecdot
likelihood
erythrocyt
lysi
urin
increas
alkalin
poorli
concentr
hyposthenur
urin
sampl
ghost
cell
provid
evid
intravascular
hemolysi
seen
smear
made
immedi
blood
collect
mechan
circul
immun
complex
deposit
activ
immun
cell
fraction
crystalliz
receptor
engag
deliveri
immunoglobulinbound
nucleic
acid
tolllik
receptor
also
occur
infect
damag
target
cell
anoth
mechan
may
make
pathogen
particularli
like
induc
autoimmun
increas
exposur
selfepitop
normal
sequest
ineffici
present
immun
cell
propos
mechan
develop
imha
contribut
acceler
clearanc
erythrocyt
plasmodium
infect
peopl
mice
also
may
occur
babesia
gibsoni
infect
dog
mycoplasma
haemof
infect
cat
antibodymedi
remov
part
normal
erythrocyt
senesc
organ
thu
may
caus
imha
amplifi
normal
antibodymedi
remov
age
damag
erythrocyt
overal
manuscript
review
high
level
evid
immunemedi
destruct
erythrocyt
contribut
anemia
dog
infect
b
gibsoni
immunemedi
hemolyt
anemia
document
dog
studi
addit
studi
number
infect
dog
imha
could
determin
provid
use
mechanist
insight
median
ime
valu
rang
babesia
speci
studi
show
intermedi
high
ime
valu
four
studi
dog
experiment
infect
b
gibsoni
yield
median
ime
valu
rang
natur
infect
b
gibsoni
occur
commonli
fight
breed
babesia
speci
specifi
like
b
rossi
nine
dog
imha
document
studi
ime
valu
thu
evid
larg
babesia
speci
caus
imha
lower
b
gibsoni
attribut
part
fact
studi
design
determin
associ
imha
infect
exist
nevertheless
differ
also
may
exist
pathogen
among
babesia
speci
influenc
risk
imha
exampl
studi
found
major
anem
b
vogeliinfect
dog
igm
igg
bound
erythrocyt
antibodi
detect
dog
infect
b
cani
studi
eccentrocytosi
suggest
oxid
damag
common
b
canisinfect
dog
ime
valu
b
cani
studi
wherea
b
voge
mechan
immunemedi
erythrocyt
destruct
b
gibsoni
infect
explor
babesia
speci
infect
erythrocyt
antibodi
appropri
target
organ
could
result
immunemedi
erythrocyt
destruct
without
target
selfantigen
howev
antibodi
produc
infect
also
appear
target
erythrocyt
membran
oxid
injuri
may
play
role
antierythrocyt
antibodi
format
activ
macrophag
caus
oxid
damag
uninfect
well
infect
erythrocyt
b
gibsoni
infect
factor
may
contribut
sever
imha
dog
addit
oxid
damag
sialic
acid
residu
remov
requir
expos
epitop
target
antibodi
interestingli
antierythrocyt
antibodi
develop
dog
experiment
infect
b
gibsoni
attach
undamag
red
blood
cell
dog
recov
clinic
infect
furthermor
vitro
studi
shown
babesiainduc
antibodi
reactiv
erythrocyt
higher
age
oxid
fresh
erythrocyt
taken
togeth
data
suggest
ongo
damag
red
cell
membran
increas
exposur
epitop
usual
hidden
facilit
immunemedi
erythrocyt
destruct
infect
control
drive
immun
ime
valu
could
calcul
total
number
dog
imha
could
discern
evid
piroplasm
particular
b
gibsoni
caus
imha
intermedi
high
b
gibsoni
evid
suggest
infect
antibodi
target
host
erythrocyt
antigen
expos
consequ
transient
oxid
damag
sialic
acid
residu
remov
studi
need
determin
differ
pathogen
among
speci
host
factor
mediat
risk
develop
imha
infect
dog
known
mechan
erythrocyt
destruct
suggest
immunosuppress
necessari
resolv
immunemedi
erythrocyt
destruct
case
nine
dog
imha
studi
infect
expos
anaplasma
phagocytophilum
median
ime
valu
rang
addit
imha
plateletbound
antibodi
document
dog
concurr
thrombocytopenia
although
dog
report
treat
concurr
doxycyclin
immunosuppress
corticosteroid
treatment
dog
respond
doxycyclin
treatment
alon
wherea
anoth
dog
prednison
discontinu
day
one
retrospect
case
seri
document
dog
acut
anaplasma
plati
infect
concurr
imha
dog
spherocytosi
posit
salin
agglutin
coomb
test
result
support
diagnosi
imha
ime
valu
studi
evid
phagocytophilum
caus
imha
low
howev
studi
report
phagocytophilum
dog
imha
limit
case
report
retrospect
studi
design
although
studi
limit
intermedi
level
evid
found
b
feli
caus
imha
cat
treatment
resolv
imha
without
immunosuppress
seven
studi
document
imha
cat
infect
hemotrop
mycoplasma
spp
yield
ime
valu
seven
studi
meet
inclus
criteria
identifi
howev
comorbid
erythroleukemia
myeloprolif
diseas
chronic
interstiti
nephriti
glomerulonephr
splenic
amyloidosi
drug
administr
document
infect
cat
preclud
ime
calcul
median
ime
valu
other
rang
consensu
summari
statement
immunemedi
hemolyt
anemia
recogn
paraneoplast
syndrom
peopl
chronic
lymphocyt
leukemia
wellestablish
caus
imha
peopl
neoplasm
associ
imha
human
causal
mechan
remain
elus
ime
valu
could
calcul
studi
figur
global
median
ime
valu
rang
thu
repres
level
evid
neglig
ime
valu
patient
low
ime
valu
patient
gener
low
level
evid
reflect
fact
major
publish
studi
specif
ask
whether
cancer
evid
causal
link
cancer
imha
dog
current
lack
veterinari
literatur
larg
reflect
fact
major
publish
studi
specif
ask
whether
cancer
associ
imha
dog
studi
need
determin
associ
exist
although
evid
causal
link
exist
cancer
elimin
potenti
trigger
diseas
five
studi
report
cat
neoplasia
imha
figur
studi
provid
neglig
evid
causal
link
neoplasia
imha
yield
median
ime
valu
rang
studi
specif
address
hypothesi
singl
retrospect
studi
cat
imha
concurr
neoplasia
present
cat
eight
cat
ime
valu
could
calcul
lymphoma
imha
identifi
two
studi
report
case
demonstr
causal
associ
imha
lymphoma
studi
consid
partial
report
suggest
causal
latter
report
sibl
specif
pathogenfre
experiment
cat
cat
lymphomalymphocyt
leukemia
diagnos
histolog
review
necropsi
howev
interpret
histolog
cat
equivoc
histolog
pattern
describ
multicentr
tlymphoblast
infiltr
associ
blymphocyt
prolifer
author
conclud
like
lymphoprolif
disord
elimin
aberr
immun
respons
singl
cat
multipl
myeloma
imha
identifi
studi
show
causal
associ
neoplasia
imha
method
diagnosi
neoplasia
unclear
evid
associ
imha
multipl
myeloma
neglig
ime
valu
three
cat
erythroleukemia
cat
nonspecifi
myeloprolif
diseas
imha
identifi
studi
demonstr
causal
associ
imha
neoplasia
report
cat
erythroleukemia
suggest
diagnosi
base
bone
marrow
cytolog
histolog
review
method
diagnosi
neoplasia
describ
third
cat
erythroleukemia
cat
nonspecifi
myeloprolif
diseas
diagnosi
base
bone
marrow
examin
detail
limit
cat
nonspecifi
myeloprolif
diseas
felv
posit
evid
causal
associ
erythroleukemia
imha
neglig
ime
valu
studi
could
assign
studi
erythroleukemia
unspecifi
myeloproliferar
diseas
yield
ime
valu
presenc
comorbid
singl
cat
histiocyt
sarcoma
imha
identifi
studi
show
causal
associ
imha
neoplasia
method
diagnosi
neoplasia
describ
yield
ime
valu
singl
case
pancreat
carcinoma
singl
case
anaplast
sarcoma
giant
cell
cat
imha
identifi
neither
studi
show
causal
associ
imha
neoplasia
evid
causal
associ
imha
carcinoma
sarcoma
neglig
ime
valu
case
one
cat
imha
uncharacter
gastrointestin
neoplasia
cat
imha
uncharacter
mass
identifi
causal
associ
imha
lesion
identifi
method
diagnosi
presum
neoplast
lesion
describ
evid
causal
associ
imha
uncharacter
gastrointestin
neoplasia
low
ime
valu
neglig
uncharacter
mass
ime
valu
current
strong
evid
exist
causal
link
cancer
imha
cat
studi
need
determin
associ
exist
nevertheless
retrospect
evid
suggest
rel
high
preval
concurr
cancer
cat
imha
inflamm
often
occur
imha
could
indirectli
lead
pancreat
activ
neutrophil
format
thromboemboli
subsequ
oxid
damag
ischem
event
may
directli
damag
pancrea
altern
inflamm
associ
pancreat
could
lead
imha
indirectli
induc
autoantibodi
form
erythrocyt
autoantibodi
bind
epitop
exocrin
pancreat
epithelium
erythrocyt
also
may
gener
date
none
hypothes
confirm
veterinari
speci
observ
concurr
pancreat
imha
report
femal
cocker
spaniel
retrospect
studi
dog
imha
figur
studi
evalu
group
dog
imha
indic
preval
concurr
pancreat
low
imha
dog
dog
studi
yield
ime
valu
pancreat
cocker
spaniel
case
report
imha
pancreat
howev
cholestasi
renal
failur
also
present
although
cholestasi
renal
failur
complic
pancreat
primari
organ
diseas
could
elimin
preclud
calcul
ime
valu
recent
studi
cat
imha
show
cat
pancreat
yield
ime
valu
studi
design
answer
question
whether
imha
associ
pancreat
anoth
larg
studi
cat
imha
indic
concurr
cholang
pancreat
ime
valu
could
calcul
inform
regard
number
cat
pancreat
alon
specifi
evid
pancreat
caus
imha
neglig
dog
neglig
low
cat
addit
studi
would
requir
establish
causal
relationship
one
studi
attribut
secondari
imha
concurr
liver
necrosi
anoth
concurr
necrot
inflamm
tail
singl
patient
studi
yield
ime
valu
evalu
patient
pursu
evid
necrosi
caus
imha
neglig
dog
report
cat
anecdot
report
suggest
gener
inflammatori
process
induc
imha
dog
cat
direct
evid
lack
welldesign
studi
determin
whether
noninfecti
inflammatori
process
caus
imha
warrant
seventeen
studi
describ
dog
imha
expos
drug
toxin
report
case
suffici
primari
data
calcul
ime
valu
major
case
dog
expos
antimicrobi
drug
case
ime
valu
rang
median
figur
highest
level
evid
ime
valu
came
unblind
random
prospect
clinic
trial
dog
given
escal
dose
cefazedon
acquir
antierythrocyt
antibodi
remain
report
case
associ
low
neglig
evid
support
drug
toxin
caus
imha
dog
figur
two
paper
describ
develop
imha
administr
propylthiouracil
cat
respect
ime
valu
first
studi
cat
cat
hyperthyroid
treat
propylthiouracil
develop
immunemedi
drug
reaction
find
follow
prospect
unblind
nonrandom
trial
healthi
cat
given
drug
caus
develop
coomb
testposit
anemia
one
addit
case
report
describ
warfarin
exposur
cat
imha
ime
valu
preval
druginduc
imha
dog
cat
either
rare
underreport
howev
lack
evid
preclud
possibl
drug
toxin
trigger
imha
effect
vaccin
elicit
robust
immun
respons
pathogen
interest
howev
vaccin
also
may
elicit
unfavor
immun
respons
result
mechan
molecular
mimicri
bystand
cell
activ
downregul
selftoler
contribut
autoimmun
three
paper
provid
evid
link
vaccin
imha
low
rang
ime
valu
public
provid
high
level
evid
support
associ
vaccin
imha
found
two
studi
report
intent
evalu
associ
vaccin
imha
retrospect
studi
associ
ime
valu
differ
found
frequenc
imha
case
diagnos
within
first
month
vaccin
diagnos
subsequ
month
wherea
similar
tempor
distribut
identifi
control
group
subsequ
studi
similar
q
score
show
differ
number
case
recent
vaccin
histori
imha
control
group
therefor
award
ime
valu
paper
review
exclud
patient
recent
vaccin
histori
intent
describ
dog
idiopath
imha
addit
paper
includ
vaccin
statu
dog
imha
data
exclud
analysi
includ
studi
uncertain
diagnosi
imha
case
studi
altern
caus
imha
possibl
case
studi
time
vaccin
specifi
studi
prospect
investig
link
vaccin
autoimmun
diseas
dog
demonstr
presenc
autoantibodi
vaccin
administr
howev
dog
follow
day
vaccin
meet
criteria
diagnosi
imha
paper
veterinari
literatur
aim
evalu
link
vaccin
imha
respect
support
refut
associ
question
whether
vaccin
trigger
imha
dog
remain
unansw
similarli
insuffici
evid
avail
determin
whether
vaccin
trigger
autoimmun
diseas
peopl
report
associ
vaccin
administr
imha
cat
found
recommend
unless
clinic
present
suggest
credibl
differenti
diagnosi
histori
help
assess
like
risk
certain
infect
thorough
physic
examin
diagnost
imag
help
identifi
potenti
nidu
infect
presenc
neoplast
lesion
pattern
abnorm
identifi
cbc
serum
biochemistri
urinalysi
increas
index
suspicion
specif
infecti
agent
may
associ
imha
minimum
databas
also
identifi
addit
patholog
process
eg
proteinuria
may
requir
specif
treatment
although
insensit
blood
f
g
u
r
e
integr
metric
evid
ime
valu
drug
horizont
dot
line
indic
threshold
ime
valu
neglig
low
low
intermedi
intermedi
high
level
evid
singl
antimicrobi
drug
yield
highlevel
evid
dog
cefazedon
nsaid
nonsteroid
antiinflammatori
drug
smear
examin
use
identifi
presenc
vectorborn
diseas
agent
although
evid
associ
urinari
tract
infect
caus
imha
neglig
identif
treatment
infect
immunosuppress
prudent
refer
reader
acvim
consensu
statement
treatment
imha
press
recommend
addit
discuss
specif
circumst
treat
subclin
bacteriuria
immunosuppress
patient
evid
gastrointestin
parasit
caus
imha
dog
low
rapid
resolut
imha
treatment
minim
immunosuppress
describ
support
inform
identif
babesia
spp
light
microscopi
blood
smear
consid
insensit
screen
cat
polymeras
chain
reaction
identifi
parasit
dna
rna
recommend
insuffici
evid
recommend
withhold
necessari
medic
dog
cat
imha
howev
medic
particularli
previous
implic
immunemedi
diseas
use
caution
patient
imha
everi
patient
ideal
complet
histori
record
includ
vaccin
drug
administ
dose
date
frequenc
durat
rout
administr
inform
product
use
manufactur
indic
specif
lot
advers
event
exposur
toxin
also
document
dog
cat
imha
evid
cefazedon
dog
propylthiouracil
cat
suggest
class
drug
may
associ
imha
small
anim
commonli
prescrib
medic
evid
base
data
analyz
propos
unifi
model
pathogenesi
imha
new
system
nomenclatur
diseas
categor
nonassoci
associ
rather
primari
secondari
respect
figur
b
clarif
need
word
primari
impli
trigger
definit
rule
wherea
secondari
impli
causat
propos
term
associ
use
comorbid
identifi
case
comorbid
might
caus
imha
secondari
imha
wherea
other
might
coincident
primari
imha
nonassoci
imha
case
comorbid
identifi
diagnost
evalu
includ
primari
idiopath
cryptogen
case
latter
impli
underli
caus
identifi
perhap
underli
pathomechan
current
understood
comorbid
could
detect
use
avail
test
vcci
task
forc
form
began
identifi
focus
question
repres
import
problem
veterinari
immunolog
name
evid
infect
neoplasia
drug
vaccin
comorbid
caus
imha
dog
cat
origin
intent
perform
systemat
review
literatur
answer
question
howev
quickli
becam
appar
studi
veterinari
literatur
design
determin
given
comorbid
caus
imha
henc
expand
approach
use
evalu
evid
present
review
critic
need
welldesign
prospect
casecontrol
clinic
studi
directli
ask
question
whether
infect
neoplasia
drug
vaccin
caus
imha
comorbid
like
caus
imha
larg
number
affect
patient
infect
express
epitop
mimick
erythrocyt
antigen
wide
express
popul
organ
caus
b
f
g
u
r
e
iceberg
model
propos
new
nomenclatur
immunemedi
hemolyt
anemia
imha
iceberg
model
posit
pathomechan
underli
imha
fall
spectrum
recogn
water
level
current
unrecogn
occult
conceal
latter
postul
major
hypothet
occult
pathomechan
list
b
propos
new
nomenclatur
imha
better
reflect
heterogen
pathomechan
underli
imha
transient
express
normal
hidden
epitop
other
might
induc
imha
patient
epigenet
genet
predisposit
given
inflammatori
context
studi
investig
individu
comorbid
trigger
imha
role
genet
epigenet
help
identifi
diseas
screen
patient
diseas
screen
select
patient
may
increas
risk
develop
imha
trigger
mechanist
studi
also
determin
comorbid
treat
lead
resolut
imha
without
need
immunosuppress
stringent
criteria
diagnosi
imha
definit
diagnosi
comorbid
must
integr
studi
design
order
make
meaning
observ
jonathan
fogl
paid
merial
speak
engag
continu
educ
linda
kidd
paid
speaker
idexx
zoeti
occasion
consult
idexx
zoeti
merck
author
conflict
interest
declar
